Statin therapy after first stroke reduces 10-year stroke recurrence and improves survival

Neurology

Volumn 72, Issue 21, 2009, Pages 1816-1822

  Milionis, H J ^a   Giannopoulos, S ^a   Kosmidou, M ^a   Panoulas, V ^a   Manios, E ^b   Kyritsis, A P ^a   Elisaf, M S ^a   Vemmos, K ^b  

^a UNIVERSITY OF IOANNINA   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FLUINDOSTATIN; PRAVASTATIN; SIMVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; CONFIDENCE INTERVAL; DRUG EFFICACY; FEMALE; FOLLOW UP; HAZARD RATIO; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RECURRENCE RISK; RECURRENT DISEASE; RETROSPECTIVE STUDY; RISK FACTOR; RISK REDUCTION; STATISTICAL ANALYSIS; STROKE; STROKE PATIENT; SURVIVAL; TREATMENT OUTCOME; BRAIN ISCHEMIA; COHORT ANALYSIS; FORECASTING; KAPLAN MEIER METHOD; MULTIVARIATE ANALYSIS; REGISTER; REGRESSION ANALYSIS;

AGED; BRAIN ISCHEMIA; COHORT STUDIES; CONFIDENCE INTERVALS; FEMALE; FOLLOW-UP STUDIES; FORECASTING; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KAPLAN-MEIERS ESTIMATE; MALE; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; RECURRENCE; REGISTRIES; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; STROKE; TREATMENT OUTCOME;

EID: 67649172890     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181a711cb     Document Type: Article

References (29)

1. Lisabeth LD, Smith MA, Brown DL, Moye LA, Risser JM, Morgenstern LB. Ethnic differences in stroke recurrence. Ann Neurol 2006;60:469-475.
2. Jorgensen HS, Nakayama H, Reith J, Raaschou HO, Olsen TS. Stroke recurrence: predictors, severity, and prognosis: The Copenhagen Stroke Study. Neurology 1997;48: 891-895.
3. Samsa GP, Bian J, Lipscomb J, Matchar DB. Epidemiology of recurrent cerebral infarction: a medicare claimsbased comparison of first and recurrent strokes on 2-year survival and cost. Stroke 1999;30:338-349.
4. Kiyohara Y, Kubo M, Kato I, et al. Ten-year prognosis of stroke and risk factors for death in a Japanese community: the Hisayama study. Stroke 2003;34:2343-2347.
5. Egido JA. Benefits of modifying the predictive factors of stroke recurrence. Cerebrovasc Dis 2005;20 suppl 2:84-90.
6. Amarenco P, Bogousslavsky J, Callahan A 3rd, et al. Highdose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006;355:549-559.
7. Rother J, Alberts MJ, Touze E, et al. Risk factor profile and management of cerebrovascular patients in the REACH Registry. Cerebrovasc Dis 2008;25:366-374.
8. Nassief A, Marsh JD. Statin therapy for stroke prevention. Stroke 2008;39:1042-1048.
9. Amarenco P, Labreuche J, Lavallee P, Touboul PJ. Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. Stroke 2004;35:2902-2909.
10. Cimino M, Gelosa P, Gianella A, Nobili E, Tremoli E, Sironi L. Statins: multiple mechanisms of action in the ischemic brain. Neuroscientist 2007;13:208-213.
11. O'Regan C, Wu P, Arora P, Perri D, Mills EJ. Statin therapy in stroke prevention: a meta-analysis involving 121,000 patients. Am J Med 2008;121:24-33.
12. Vemmos KN, Takis CE, Georgilis K, et al. The Athens stroke registry: results of a five-year hospital-based study. Cerebrovasc Dis 2000;10:133-141.
13. Adams HP Jr, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial TOAST Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993;24:35-41.
14. Stavem K, Lossius M, Ronning OM. Reliability and validity of the Canadian Neurological Scale in retrospective assessment of initial stroke severity. Cerebrovasc Dis 2003; 16:286-291.
15. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497.
16. Hacke W, Kaste M, Skyhoj Olsen T, Bogousslavsky J, Orgogozo JM. Acute treatment of ischemic stroke. European Stroke Initiative (EUSI). Cerebrovasc Dis 2000;10 suppl 3:22-33.
17. Sacco RL, Foulkes MA, Mohr JP, Wolf PA, Hier DB, Price TR. Determinants of early recurrence of cerebral infarction: The Stroke Data Bank. Stroke 1989;20:983-989.
18. Toni D, Fiorelli M, Gentile M, et al. Progressing neurological deficit secondary to acute ischemic stroke: a study on predictability, pathogenesis, and prognosis. Arch Neurol 1995;52:670-675.
19. Mazighi M, Lavallee PC, Labreuche J, Amarenco P. Statin therapy and stroke prevention: what was known, what is new and what is next? Curr Opin Lipidol 2007;18:622-625.
20. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective metaanalysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-1278.
21. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-1435.
22. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebocontrolled trial. Lancet 2004;364:685-696.
23. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361: 1149-1158.
24. Goldstein LB, Amarenco P, Lamonte M, et al. Relative effects of statin therapy on stroke and cardiovascular events in men and women: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study. Stroke 2008;39:2444-2448.
25. Chaturvedi S, Zivin J, Breazna A, et al. Effect of atorvastatin in elderly patients with a recent stroke or transient ischemic attack. Neurology 2009;72:688-694.
26. Vaughan CJ, Delanty N, Basson CT. Do statins afford neuroprotection in patients with cerebral ischaemia and stroke? CNS Drugs 2001;15:589-596.
27. Colivicchi F, Bassi A, Santini M, Caltagirone C. Discontinuation of statin therapy and clinical outcome after ischemic stroke. Stroke 2007;38:2652-2657.
28. Athyros VG, Kakafika AI, Tziomalos K, Papageorgiou AA, Karagiannis A. Statins for the prevention of first or recurrent stroke. Curr Vasc Pharmacol 2008;6:124-133.
29. Paciaroni M, Hennerici M, Agnelli G, Bogousslavsky J. Statins and stroke prevention. Cerebrovasc Dis 2007;24: 170-182.